Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.64 USD
+0.04 (2.50%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.62 -0.02 (-1.22%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PSTV 1.64 +0.04(2.50%)
Will PSTV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PSTV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PSTV
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
PSTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Other News for PSTV
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics presents data at 2024 CNS Annual Meeting
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials
Buy Rating Affirmed for Plus Therapeutics Amidst Promising Clinical Trial Results